SlideShare uma empresa Scribd logo
1 de 37
Endoscopic management of
bleeding PUD.
Dr. Kagaruki
Facilitator: Dr. Mwanga
OBJECTIVE
Pre-endoscopic management
Endoscopic management
 Adrenaline Injection
 Sclerosant injection
 Thrombin Fibrin sealant
 Thermal application
Mechanical
Endoscopic clipping
Introduction
• PUD is the most common cause of non-variceal bleeding.
• Account for 40-50% of UGIB.
• Bleeding is the most common cause of ulcer-related death.
Fortunately 80% of bleeding pud stop spontaneously and not rebleed.
• Most mortality occurred in high risk patients.
• Overall mortality rate 5 to 10%.
• Need for selection of high risk patients.
Etiology
• Helicobacter pylori infection
• NSAID
• Stress-related
• Zollinger Ellison syndrome
Clinical Presentation
• Hematemesis and melena and sometime hematochezia
• Resting tachycardia(HR> 100bpm), or
• orthostatic changes (HR >20bpm or SBP lower by 20mmHg on standing).
Pre-endoscopic Management
• Airway control and protection (in high risk of aspiration).
• Volume resuscitation with crystalloid fluid and blood.
• Gastric lavage using Naso/Orogastric tube which is diagnostic and facilitate future
endoscopic visualization. 15% will have no bloody or coffee ground material on
NGT-aspirates are found to have high risk lesions on endoscopy
• Promotility agent such as iv erythromycin 250mg 30min to 60minutes before
endoscope/metoclopramide prior to endoscope help clearance of upper git.
Cont…
• High dose PPI infusion reduces the severity of bleeding and the need
for endoscopic treatment.
• Correct coagulopathy if present INR<1.5 and Platelet>50x109/l.
• Obtain the initial CBC, Electrolytes, RFT and cross-match blood
• Transfusion of Blood product 1:1:1.
Cont…
• Most patient the bleeding will stop except for 20% of high risk patients which
predispose to rebleeding.
• Rebleeding rate after endoscopic therapy 5-20%.
• Features for high risk of severe UGIB include:
• Age older than 60 years
• Concomitant liver disease
• Witness hematemesis or hematochezia (ongoing bleeding)
• Hemodynamic unstable during presentation
• Onset in the hospital
• Large PUD > 2 cm
• These patients require early endoscopy.
Indications
• After adequate resuscitation and within 24 hour after initial bleeding.
• Emergency endoscopy required if hemodynamically unstable after resuscitation.
Risk assessment
1. Rockall score:
Good for prediction of mortality and rebleeding in patient with Upper GI bleeding.
Score of 0 indicate the extremely low risk of rebleed or death and may be suitable
for early discharge or no admission (pre-endoscopic)
Score Value of <3 post-endoscopic have a low risk to rebleeding or death and can be
considered for early discharge
2Score <2 mean low risk of adverse outcome.
Rockall score
2. Glasgow Blatchford score
Glasgow Blatchford score can be used to predict rebleeding and the
need for endoscopic therapy.
The score range from 0-23, with higher scores corresponding to
increasing acuity and mortality.
A score of O indicates the low risk to complications and need to be
discharged or no need for admission.
Glasgow Blatchford score
• During endoscopic the lesion may be classified according to stigmata
or recent hemorrhage which predict the rate of rebleeding.
• In patient with major stigmata of recent hemorrhage (active arterial
spurt, oozing and visible nonbleeding vessel have a high risk of
rebleeding
• Need Endoscopic hemostasis treatment , significantly reduces rates of
rebleeding, blood transfusions requirement, and need for surgical
intervention.
Endoscopic hemostasis
• Categorized into three:
Injection therapy
Thermal hemostasis
Mechanical hemostasis
• Combination of these method achieve best outcome.
Injection therapy
• Most commonly practiced hemostasis.
Include the use of diluted epinephrine, absolute alcohol, thrombin, and
fibrin sealant.
1. Diluted Epinephrine 1:10000-1:100000,injected submucosally;
work by local tamponade on vessel and vasoconstrictive effect.
• Larger volume injection 13-20ml more effective in preventing
rebleeding compared to small volume 5ml.
• It is safe to the tissues systemic complication rare but caution in
patient with Liver disease or ischemic heart disease.
2. Sclerotherapy
Injection of sclerosant:
 polidocanol,
ethanolamine,
sodium tetradecyl sulfate (STD), and
absolute ethanol.
• Cause tissue necrosis and ulceration. The effect more with increasing
dose hence they have limited volume.
Thrombin and Fibrin sealant
• Fibrin sealant consists of two components: fibrinogen and thrombin
(reconstituted with calcium chloride solution and aprotinin).
• In ulcers with active bleeding, preinjection with epinephrine is
required.
• Four quadrants around the bleeding point are injected, each with
0.5mL of fibrinogen and thrombin (a total of 1mL fibrin sealant).
• After each injection, with the needle remaining in tissue, the
reconstituted sealant is immediately followed by 1.0–1.5mL of normal
saline in order to drive the sealant submucosally.
• Following four-quadrant injection, the bleeding point is then injected.
Thermal method
• Two methods
• Contact method heater probe and multipolar probe
• Non-contact neodymium: yttrium-aluminum-garnet laser and argon plasma
coagulation.
1. Contact methods using coaptive coagulation involved the use of a hemostat to
tamponade blood flow and coapt the vessel walls, followed by the application of
cautery to thermally seal the vessel.
• Effectively in sealing medium size arteries up to 2 mm in diameter.
CONT…
2. Non-contact method Argon plasma coagulation (APC) and laser deliver thermal
energy without contacting the tissue.
• Heating of tissue protein, contraction of the arterial wall, and vessel shrinkage.
However, there is a “heat-sink” effect from flowing arterial blood, leading to the
dissipation of thermal energy.
• Less effective for vessels >0.25mm and deeper bleeding. The burn is superficial
hence less risk for perforation but complications git overdistention.
Mechanical
• Endoscopic clip provide direct tissue approximation and superficial vessel closure.
• Clips are loaded through the instrument channel and are generally made of a two-
pronged metal clip attached to a deployment handle that allows opening, closing,
and firing of the clip.
• The handles allow rotation of the clip to facilitate positioning.
What is the role of second-look endoscopy in the
treatment of upper gastrointestinal bleeding
(UGIB)?
• A second attempt at endoscopic control is warranted if the initial
endoscopy fails to control the bleeding.
• Some authorities have concerns about the perils of a second
esophagogastroduodenoscopy (EGD), which may result in delayed surgery,
perforation, and increased morbidity and mortality.
• However, this approach has been validated in a large, randomized,
controlled trial that showed decreased morbidity and mortality
• Controversial, may be considered in select group of patients.
• For example obscured vision, inadequate endoscopic therapy.
References
• Shackelford surgery of alimentary tract 8th edition
• Gastrointestinal endoscopy in practice
• Gastroenterological endoscope 2nd edition

Mais conteúdo relacionado

Semelhante a 11. Endoscopic management of bleeding PUD.pptx

Upper gastrointestinal tract bleeding(ugib)
Upper gastrointestinal tract bleeding(ugib)Upper gastrointestinal tract bleeding(ugib)
Upper gastrointestinal tract bleeding(ugib)
Joseph Ofoegbu
 

Semelhante a 11. Endoscopic management of bleeding PUD.pptx (20)

Upper gastrointestinal tract bleeding(ugib)
Upper gastrointestinal tract bleeding(ugib)Upper gastrointestinal tract bleeding(ugib)
Upper gastrointestinal tract bleeding(ugib)
 
DVT AND ANEURYSMS.pptx
DVT AND ANEURYSMS.pptxDVT AND ANEURYSMS.pptx
DVT AND ANEURYSMS.pptx
 
Deep venous thrombosis
Deep venous thrombosisDeep venous thrombosis
Deep venous thrombosis
 
GIT Kurdistan Board GEH Journal club Lower GIB 2014.
GIT Kurdistan Board GEH Journal club Lower GIB 2014.GIT Kurdistan Board GEH Journal club Lower GIB 2014.
GIT Kurdistan Board GEH Journal club Lower GIB 2014.
 
Git Gib 2010 plus Pictures.
Git Gib 2010 plus Pictures.Git Gib 2010 plus Pictures.
Git Gib 2010 plus Pictures.
 
UPPER GIT BLEEDING.pdf
UPPER  GIT BLEEDING.pdfUPPER  GIT BLEEDING.pdf
UPPER GIT BLEEDING.pdf
 
UGIB - ppt 2023.pptx
UGIB - ppt 2023.pptxUGIB - ppt 2023.pptx
UGIB - ppt 2023.pptx
 
splenictrauma-190910140837 (1).pdf
splenictrauma-190910140837 (1).pdfsplenictrauma-190910140837 (1).pdf
splenictrauma-190910140837 (1).pdf
 
splenictrauma-190910140837 (1).pdf
splenictrauma-190910140837 (1).pdfsplenictrauma-190910140837 (1).pdf
splenictrauma-190910140837 (1).pdf
 
Splenic trauma - Causes, Complications, Management
Splenic trauma - Causes, Complications, ManagementSplenic trauma - Causes, Complications, Management
Splenic trauma - Causes, Complications, Management
 
Neo innovation in Limb Ischemia Management
Neo innovation in Limb Ischemia ManagementNeo innovation in Limb Ischemia Management
Neo innovation in Limb Ischemia Management
 
Endoscopic Hemostasis - for Endoscopy Nurses
Endoscopic Hemostasis - for Endoscopy NursesEndoscopic Hemostasis - for Endoscopy Nurses
Endoscopic Hemostasis - for Endoscopy Nurses
 
Lower gi bleeding
Lower gi bleeding Lower gi bleeding
Lower gi bleeding
 
EMR/ endoscopic mucosal resection
EMR/ endoscopic mucosal resectionEMR/ endoscopic mucosal resection
EMR/ endoscopic mucosal resection
 
damage control resucitation.pptx
damage control resucitation.pptxdamage control resucitation.pptx
damage control resucitation.pptx
 
Chronic renal failure, surgical management
Chronic renal failure, surgical managementChronic renal failure, surgical management
Chronic renal failure, surgical management
 
Complication of Mitral valve replacement surgery
Complication of Mitral valve replacement surgeryComplication of Mitral valve replacement surgery
Complication of Mitral valve replacement surgery
 
Anaethetic management of scoliotic patients
Anaethetic management of scoliotic patientsAnaethetic management of scoliotic patients
Anaethetic management of scoliotic patients
 
Managing acute upper gi bleeding
Managing acute upper gi bleedingManaging acute upper gi bleeding
Managing acute upper gi bleeding
 
Shock dept surg_vmc_knl
Shock dept surg_vmc_knlShock dept surg_vmc_knl
Shock dept surg_vmc_knl
 

Mais de Amos Brighton

Mais de Amos Brighton (20)

Materials on the management of Seizure Disorders.pptx
Materials on the management of Seizure Disorders.pptxMaterials on the management of Seizure Disorders.pptx
Materials on the management of Seizure Disorders.pptx
 
SURGICAL COMPLICATIONS OF PUD md 5 july.pptx
SURGICAL COMPLICATIONS OF PUD md 5 july.pptxSURGICAL COMPLICATIONS OF PUD md 5 july.pptx
SURGICAL COMPLICATIONS OF PUD md 5 july.pptx
 
QUIZ OSCE (1).pptx
QUIZ OSCE (1).pptxQUIZ OSCE (1).pptx
QUIZ OSCE (1).pptx
 
16. laparascopic appendectomy 1.pptx
16. laparascopic appendectomy 1.pptx16. laparascopic appendectomy 1.pptx
16. laparascopic appendectomy 1.pptx
 
6. INDICATIONS OF UPPER GI ENDOSCOPY AND PATIENT PREPARATIONS.pptx
6. INDICATIONS OF UPPER GI ENDOSCOPY AND PATIENT PREPARATIONS.pptx6. INDICATIONS OF UPPER GI ENDOSCOPY AND PATIENT PREPARATIONS.pptx
6. INDICATIONS OF UPPER GI ENDOSCOPY AND PATIENT PREPARATIONS.pptx
 
2. SET UP FOR LAPAROSCOPIC SURGERY phase 3 (1).ppt
2. SET UP FOR LAPAROSCOPIC SURGERY phase 3 (1).ppt2. SET UP FOR LAPAROSCOPIC SURGERY phase 3 (1).ppt
2. SET UP FOR LAPAROSCOPIC SURGERY phase 3 (1).ppt
 
8. Upper GI findings.pptx
8. Upper GI findings.pptx8. Upper GI findings.pptx
8. Upper GI findings.pptx
 
CASE PRESENTATION - MONDAY.pptx
CASE PRESENTATION - MONDAY.pptxCASE PRESENTATION - MONDAY.pptx
CASE PRESENTATION - MONDAY.pptx
 
ADVANCED GASTRIC CANCER RX.pptx
ADVANCED GASTRIC CANCER RX.pptxADVANCED GASTRIC CANCER RX.pptx
ADVANCED GASTRIC CANCER RX.pptx
 
GIST.pptx
GIST.pptxGIST.pptx
GIST.pptx
 
effusion.pptx
effusion.pptxeffusion.pptx
effusion.pptx
 
ERCP.pptx
ERCP.pptxERCP.pptx
ERCP.pptx
 
7. TYMPAMOPLASTY, OCR, STAPEDOTOMY PRESENTATION.pptx
7. TYMPAMOPLASTY,  OCR, STAPEDOTOMY PRESENTATION.pptx7. TYMPAMOPLASTY,  OCR, STAPEDOTOMY PRESENTATION.pptx
7. TYMPAMOPLASTY, OCR, STAPEDOTOMY PRESENTATION.pptx
 
1. MAXILLECTOMY.pptx
1. MAXILLECTOMY.pptx1. MAXILLECTOMY.pptx
1. MAXILLECTOMY.pptx
 
L26.HEPATIC TUMORS.pptx
L26.HEPATIC TUMORS.pptxL26.HEPATIC TUMORS.pptx
L26.HEPATIC TUMORS.pptx
 
PATHOPHYSIOLOGY OF PEPTIC ULCER DISEASE.pptx
PATHOPHYSIOLOGY OF PEPTIC ULCER DISEASE.pptxPATHOPHYSIOLOGY OF PEPTIC ULCER DISEASE.pptx
PATHOPHYSIOLOGY OF PEPTIC ULCER DISEASE.pptx
 
Degenerative conditions.pptx
Degenerative conditions.pptxDegenerative conditions.pptx
Degenerative conditions.pptx
 
Muttaz Degenerative spine.pptx
Muttaz Degenerative spine.pptxMuttaz Degenerative spine.pptx
Muttaz Degenerative spine.pptx
 
PELVIC.pptx
PELVIC.pptxPELVIC.pptx
PELVIC.pptx
 
1-a. CARDIOLVASCULAR PRES FN.pptx
1-a. CARDIOLVASCULAR PRES FN.pptx1-a. CARDIOLVASCULAR PRES FN.pptx
1-a. CARDIOLVASCULAR PRES FN.pptx
 

Último

Último (20)

UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Plant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptxPlant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptx
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 

11. Endoscopic management of bleeding PUD.pptx

  • 1. Endoscopic management of bleeding PUD. Dr. Kagaruki Facilitator: Dr. Mwanga
  • 2. OBJECTIVE Pre-endoscopic management Endoscopic management  Adrenaline Injection  Sclerosant injection  Thrombin Fibrin sealant  Thermal application Mechanical Endoscopic clipping
  • 3. Introduction • PUD is the most common cause of non-variceal bleeding. • Account for 40-50% of UGIB. • Bleeding is the most common cause of ulcer-related death. Fortunately 80% of bleeding pud stop spontaneously and not rebleed. • Most mortality occurred in high risk patients. • Overall mortality rate 5 to 10%. • Need for selection of high risk patients.
  • 4. Etiology • Helicobacter pylori infection • NSAID • Stress-related • Zollinger Ellison syndrome
  • 5. Clinical Presentation • Hematemesis and melena and sometime hematochezia • Resting tachycardia(HR> 100bpm), or • orthostatic changes (HR >20bpm or SBP lower by 20mmHg on standing).
  • 6. Pre-endoscopic Management • Airway control and protection (in high risk of aspiration). • Volume resuscitation with crystalloid fluid and blood. • Gastric lavage using Naso/Orogastric tube which is diagnostic and facilitate future endoscopic visualization. 15% will have no bloody or coffee ground material on NGT-aspirates are found to have high risk lesions on endoscopy • Promotility agent such as iv erythromycin 250mg 30min to 60minutes before endoscope/metoclopramide prior to endoscope help clearance of upper git.
  • 7. Cont… • High dose PPI infusion reduces the severity of bleeding and the need for endoscopic treatment. • Correct coagulopathy if present INR<1.5 and Platelet>50x109/l. • Obtain the initial CBC, Electrolytes, RFT and cross-match blood • Transfusion of Blood product 1:1:1.
  • 8. Cont… • Most patient the bleeding will stop except for 20% of high risk patients which predispose to rebleeding. • Rebleeding rate after endoscopic therapy 5-20%. • Features for high risk of severe UGIB include: • Age older than 60 years • Concomitant liver disease • Witness hematemesis or hematochezia (ongoing bleeding) • Hemodynamic unstable during presentation • Onset in the hospital • Large PUD > 2 cm • These patients require early endoscopy.
  • 9. Indications • After adequate resuscitation and within 24 hour after initial bleeding. • Emergency endoscopy required if hemodynamically unstable after resuscitation.
  • 10.
  • 11. Risk assessment 1. Rockall score: Good for prediction of mortality and rebleeding in patient with Upper GI bleeding. Score of 0 indicate the extremely low risk of rebleed or death and may be suitable for early discharge or no admission (pre-endoscopic) Score Value of <3 post-endoscopic have a low risk to rebleeding or death and can be considered for early discharge 2Score <2 mean low risk of adverse outcome.
  • 13. 2. Glasgow Blatchford score Glasgow Blatchford score can be used to predict rebleeding and the need for endoscopic therapy. The score range from 0-23, with higher scores corresponding to increasing acuity and mortality. A score of O indicates the low risk to complications and need to be discharged or no need for admission.
  • 15. • During endoscopic the lesion may be classified according to stigmata or recent hemorrhage which predict the rate of rebleeding. • In patient with major stigmata of recent hemorrhage (active arterial spurt, oozing and visible nonbleeding vessel have a high risk of rebleeding • Need Endoscopic hemostasis treatment , significantly reduces rates of rebleeding, blood transfusions requirement, and need for surgical intervention.
  • 16.
  • 17.
  • 18.
  • 19. Endoscopic hemostasis • Categorized into three: Injection therapy Thermal hemostasis Mechanical hemostasis • Combination of these method achieve best outcome.
  • 20. Injection therapy • Most commonly practiced hemostasis. Include the use of diluted epinephrine, absolute alcohol, thrombin, and fibrin sealant. 1. Diluted Epinephrine 1:10000-1:100000,injected submucosally; work by local tamponade on vessel and vasoconstrictive effect. • Larger volume injection 13-20ml more effective in preventing rebleeding compared to small volume 5ml. • It is safe to the tissues systemic complication rare but caution in patient with Liver disease or ischemic heart disease.
  • 21.
  • 22.
  • 23.
  • 24. 2. Sclerotherapy Injection of sclerosant:  polidocanol, ethanolamine, sodium tetradecyl sulfate (STD), and absolute ethanol. • Cause tissue necrosis and ulceration. The effect more with increasing dose hence they have limited volume.
  • 25. Thrombin and Fibrin sealant • Fibrin sealant consists of two components: fibrinogen and thrombin (reconstituted with calcium chloride solution and aprotinin).
  • 26.
  • 27. • In ulcers with active bleeding, preinjection with epinephrine is required. • Four quadrants around the bleeding point are injected, each with 0.5mL of fibrinogen and thrombin (a total of 1mL fibrin sealant). • After each injection, with the needle remaining in tissue, the reconstituted sealant is immediately followed by 1.0–1.5mL of normal saline in order to drive the sealant submucosally. • Following four-quadrant injection, the bleeding point is then injected.
  • 28. Thermal method • Two methods • Contact method heater probe and multipolar probe • Non-contact neodymium: yttrium-aluminum-garnet laser and argon plasma coagulation. 1. Contact methods using coaptive coagulation involved the use of a hemostat to tamponade blood flow and coapt the vessel walls, followed by the application of cautery to thermally seal the vessel. • Effectively in sealing medium size arteries up to 2 mm in diameter.
  • 29.
  • 30.
  • 31.
  • 32. CONT… 2. Non-contact method Argon plasma coagulation (APC) and laser deliver thermal energy without contacting the tissue. • Heating of tissue protein, contraction of the arterial wall, and vessel shrinkage. However, there is a “heat-sink” effect from flowing arterial blood, leading to the dissipation of thermal energy. • Less effective for vessels >0.25mm and deeper bleeding. The burn is superficial hence less risk for perforation but complications git overdistention.
  • 33. Mechanical • Endoscopic clip provide direct tissue approximation and superficial vessel closure. • Clips are loaded through the instrument channel and are generally made of a two- pronged metal clip attached to a deployment handle that allows opening, closing, and firing of the clip. • The handles allow rotation of the clip to facilitate positioning.
  • 34.
  • 35.
  • 36. What is the role of second-look endoscopy in the treatment of upper gastrointestinal bleeding (UGIB)? • A second attempt at endoscopic control is warranted if the initial endoscopy fails to control the bleeding. • Some authorities have concerns about the perils of a second esophagogastroduodenoscopy (EGD), which may result in delayed surgery, perforation, and increased morbidity and mortality. • However, this approach has been validated in a large, randomized, controlled trial that showed decreased morbidity and mortality • Controversial, may be considered in select group of patients. • For example obscured vision, inadequate endoscopic therapy.
  • 37. References • Shackelford surgery of alimentary tract 8th edition • Gastrointestinal endoscopy in practice • Gastroenterological endoscope 2nd edition

Notas do Editor

  1. The score less than 2 meaning low rate of bleeding, recurrence and mortality.